Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis.
Antibodies, Monoclonal, Murine-Derived
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
CD47 Antigen
/ metabolism
Cell Line, Tumor
Cyclophosphamide
/ therapeutic use
Doxorubicin
/ therapeutic use
Gene Expression Regulation, Neoplastic
Humans
Lymphoma, Large B-Cell, Diffuse
/ drug therapy
Macrophages
/ metabolism
Phagocytosis
Prednisone
/ therapeutic use
RNA, Messenger
/ genetics
Rituximab
Signaling Lymphocytic Activation Molecule Family
/ genetics
Survival Analysis
Vincristine
/ therapeutic use
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
01 02 2019
01 02 2019
Historique:
received:
02
08
2018
accepted:
11
12
2018
entrez:
3
2
2019
pubmed:
3
2
2019
medline:
2
4
2019
Statut:
epublish
Résumé
CD47 is a prominent new target in cancer immunotherapy, with antagonistic antibodies currently being evaluated in clinical trials. For effective evaluation of this strategy it is crucial to identify which patients are suited for CD47-targeted therapy. In this respect, expression of the pro-phagocytic signal SLAMF7 on both macrophages and cancer cells was recently reported to be a requisite for CD47 antibody-mediated phagocytosis. Here, we demonstrate that in fact SLAMF7 expression on cancer cells is not required and does not impact on CD47 antibody therapy. Moreover, SLAMF7 also does not impact on phagocytosis induction by CD20 antibody rituximab nor associates with overall survival of Diffuse Large B-Cell Lymphoma patients. In contrast, expression of CD47 negatively impacts on overall and progression free survival. In conclusion, cancer cell expression of SLAMF7 is not required for phagocytosis and, in contrast to CD47 expression, should not be used as selection criterion for CD47-targeted therapy.
Identifiants
pubmed: 30710089
doi: 10.1038/s41467-018-08013-z
pii: 10.1038/s41467-018-08013-z
pmc: PMC6358615
doi:
Substances chimiques
Antibodies, Monoclonal, Murine-Derived
0
CD47 Antigen
0
CD47 protein, human
0
R-CHOP protocol
0
RNA, Messenger
0
SLAMF7 protein, human
0
Signaling Lymphocytic Activation Molecule Family
0
Rituximab
4F4X42SYQ6
Vincristine
5J49Q6B70F
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Prednisone
VB0R961HZT
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
533Références
Nat Immunol. 2018 Jan;19(1):76-84
pubmed: 29180808
J Immunol. 2009 Apr 1;182(7):4415-22
pubmed: 19299742
J Immunol. 2005 Dec 15;175(12):7781-7
pubmed: 16339510
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Cell. 2010 Sep 3;142(5):699-713
pubmed: 20813259
Clin Cancer Res. 2008 May 1;14(9):2775-84
pubmed: 18451245
Nat Genet. 2015 Feb;47(2):115-25
pubmed: 25581432
Exp Hematol. 2016 Dec;44(12):1188-1196.e6
pubmed: 27616637
Trends Cell Biol. 2001 Mar;11(3):130-5
pubmed: 11306274
N Engl J Med. 2015 Aug 13;373(7):621-31
pubmed: 26035255
J Clin Invest. 2016 Jul 1;126(7):2610-20
pubmed: 27294525
Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6662-7
pubmed: 22451913
Nat Immunol. 2007 Dec;8(12):1287-9
pubmed: 18026079
Curr Opin Immunol. 2009 Feb;21(1):47-52
pubmed: 19223164
Science. 2016 Apr 8;352(6282):227-31
pubmed: 26966191
Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5
pubmed: 23193258
J Natl Cancer Inst. 2016 Oct 13;109(1):
pubmed: 27737921
PLoS One. 2012;7(9):e45466
pubmed: 23029029
Nature. 2017 Apr 27;544(7651):493-497
pubmed: 28424516
Immunity. 2014 Jul 17;41(1):49-61
pubmed: 25035953